Eisaku Yoshida

2.2k total citations · 1 hit paper
36 papers, 1.8k citations indexed

About

Eisaku Yoshida is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Eisaku Yoshida has authored 36 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Eisaku Yoshida's work include Hepatitis B Virus Studies (6 papers), HER2/EGFR in Cancer Research (4 papers) and Epigenetics and DNA Methylation (4 papers). Eisaku Yoshida is often cited by papers focused on Hepatitis B Virus Studies (6 papers), HER2/EGFR in Cancer Research (4 papers) and Epigenetics and DNA Methylation (4 papers). Eisaku Yoshida collaborates with scholars based in Japan, India and United States. Eisaku Yoshida's co-authors include Akiyoshi Fukamizu, Makoto Miyagishi, Ken Itoh, Masayuki Yamamoto, Yasutake Katoh, Susumu Nishimura, Ikuko Suzuki‐Takahashi, Hideaki Higashi, Masatoshi Kitagawa and Katsuyuki Yaginuma and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Eisaku Yoshida

35 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2.

1996 518 citations Masatoshi Kitagawa, Hideaki Higashi et al. profile →

Peers

Countries citing papers authored by Eisaku Yoshida

Since Specialization

Citations

This map shows the geographic impact of Eisaku Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eisaku Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eisaku Yoshida more than expected).

Fields of papers citing papers by Eisaku Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eisaku Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eisaku Yoshida. The network helps show where Eisaku Yoshida may publish in the future.

Co-authorship network of co-authors of Eisaku Yoshida

This figure shows the co-authorship network connecting the top 25 collaborators of Eisaku Yoshida. A scholar is included among the top collaborators of Eisaku Yoshida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eisaku Yoshida. Eisaku Yoshida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma 2025 ·PubMed ·Takeshi Terashima, Kouki Nio, Naohiko Koshikawa, Makoto Ueno, Tadashi Toyama, Masaki Miyazawa, Tomoyuki Hayashi, Akihiro Seki, Hidetoshi Nakagawa, Noriho Iida, Shinya Yamada, Hajime Takatori, Tetsuro Shimakami, Toru Yoshimura, Eisaku Yoshida, Masatoshi Nakagawa, Motoharu Seiki, Taro Yamashita	1
2	EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma 2023 ·Cancer Research Communications ·Shinya Sato, Masatoshi Nakagawa, Takeshi Terashima, Soichiro Morinaga, Yohei Miyagi, Eisaku Yoshida, Toru Yoshimura, Motoharu Seiki, Shuichi Kaneko, Makoto Ueno, Taro Yamashita, Naohiko Koshikawa	3
3	Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer 2017 ·Biomarker Research ·Masatoshi Nakagawa, Takashi Karashima, Masayuki Kamada, Eisaku Yoshida, Toru Yoshimura, Masanori Nojima, Keiji Inoue, Taro Shuin, Motoharu Seiki, Naohiko Koshikawa	8
4	Serum monomeric laminin‐γ2 as a novel biomarker for hepatocellular carcinoma 2017 ·Cancer Science ·(unknown), Hiroshi Yasuda, Ritsuko Oikawa, Chiaki Okuse, Nobuyuki Matsumoto, Hiroki Ikeda, Tsunamasa Watanabe, Hiroyuki Yamamoto, Fumio Itoh, Takehito Otsubo, Toru Yoshimura, Eisaku Yoshida, Masatoshi Nakagawa, Naohiko Koshikawa, Motoharu Seiki	17
5	Cooperative Interaction of EWS with CREB-binding Protein Selectively Activates Hepatocyte Nuclear Factor 4-mediated Transcription 2003 ·Journal of Biological Chemistry ·Natsumi Araya, Keiko Hirota, Yoko Shimamoto, Makoto Miyagishi, Eisaku Yoshida, Junji Ishida, Setsuko Kaneko, Michio Kaneko, Toshihiro Nakajima, Akiyoshi Fukamizu	76
6	Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription 2001 ·Genes to Cells ·Yasutake Katoh, Ken Itoh, Eisaku Yoshida, Makoto Miyagishi, Akiyoshi Fukamizu, Masayuki Yamamoto	440
7	Regulation of Lef-mediated Transcription and p53-dependent Pathway by Associating β-Catenin with CBP/p300 2000 ·Journal of Biological Chemistry ·Makoto Miyagishi, Ryouji Fujii, Mitsutoki Hatta, Eisaku Yoshida, Natsumi Araya, Akira Nagafuchi, Satoru Ishihara, Toshihiro Nakajima, Akiyoshi Fukamizu	106
8	Isolation and characterization of 5′‐regulatory region of mouse activin ßa subunit gene 1998 ·IUBMB Life ·Eisaku Yoshida, Keiji Tanimoto, Kazuo Murakami, Akiyoshi Fukamizu	7
9	Identification of N-terminal minimal transactivation domain of CBP, p300 and Caenorhabditis elegans homologues 1998 ·Gene ·Eisaku Yoshida, Toshihiro Nakajima, (unknown), Akiyoshi Fukamizu	10
10	Functional Association between CBP and HNF4 inTrans-activation 1997 ·Biochemical and Biophysical Research Communications ·Eisaku Yoshida, Satoko Aratani, (unknown), Makoto Miyagishi, (unknown), (unknown), Kazuo Murakami, Akiyoshi Fukamizu	93
11	Effects of Exogenous p16INK4aon Growth of Cells with Various Status of Cell-Cycle Regulators 1997 ·Biochemical and Biophysical Research Communications ·Ikuko Suzuki‐Takahashi, Hideaki Higashi, Eisaku Yoshida, Susumu Nishimura, Masatoshi Kitagawa	7
12	Expression of p16INK4aSuppresses the Unbounded and Anchorage-Independent Growth of a Glioblastoma Cell Line That Lacks p16INK4a 1997 ·Biochemical and Biophysical Research Communications ·Hideaki Higashi, Ikuko Suzuki‐Takahashi, Eisaku Yoshida, Susumu Nishimura, Masatoshi Kitagawa	15
13	Down regulation of epidermal growth factor receptors in rat hepatocytes treated with clofibric acid 1997 ·Toxicology Letters ·(unknown), Eisaku Yoshida, Hiroyuki Ishizaki, (unknown), (unknown), Fumihiko Ikemoto, Kunio Doi	2
14	BE-23372M, a novel protein tyrosine kinase inhibitor. II. Physico-chemical properties and structure elucidation. 1994 ·The Journal of Antibiotics ·Seiichi Tanaka, Takayoshi Okabe, (unknown), Eisaku Yoshida, Hiroyuki Suda	7
15	BE‐23372M, a Novel and Specific Inhibitor for Epidermal Growth Factor Receptor Kinase 1994 ·Japanese Journal of Cancer Research ·Seiichi Tanaka, Takayoshi Okabe, (unknown), Kaori Endo, (unknown), Akira Okura, Eisaku Yoshida	9
16	BE-23372M, a novel protein tyrosine kinase inhibitor. I. Producing organism, fermentation, isolation and biological activities. 1994 ·The Journal of Antibiotics ·Takayoshi Okabe, Eisaku Yoshida, (unknown), Kaori Endo, (unknown), (unknown), Seiichi Tanaka, Akira Okura, Hiroyuki Suda	11
17	Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. 1993 ·PubMed ·Tomoko Yoshinari, Akira Yamada, Daisuke Uemura, (unknown), Hiroharu Arakawa, KATSUHISA KOJIRI, Eisaku Yoshida, Hiroyuki Suda, Akira Okura	54
18	The effect of kazusamycin B on the cell cycle and morphology of cultured L1210 cells. 1988 ·The Journal of Antibiotics ·(unknown), Eisaku Yoshida, Takéo Takahashi, Akira Okura, Masanori Okanishi, Kanki Komiyama, IWAO UMEZAWA	3
19	Direct evidence for the expression of integrated hepatitis B virus DNA in human hepatoma tissue. 1984 ·PubMed ·Katsuyuki Yaginuma, (unknown), Eisaku Yoshida, Midori Kobayashi, Katsuro Koike	13
20	Rearrangement of the surface antigen gene of hepatitis B virus integrated in the human bepatoma cell lines 1983 ·Nucleic Acids Research ·Katsuro Koike, Midori Kobayashi, Hiroshi Mizusawa, Eisaku Yoshida, Katsuyuki Yaginuma, Masanori Taira	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact